Turkish Journal of Medical Sciences
Volume 46

Number 6

Article 2

1-1-2016

Hormone therapy in hypospadias surgery: a survey on the current
practice in Turkey
GÜLNUR GÖLLÜ BAHADIR
ERGUN ERGÜN
ONUR TELLİ
FARİD KHANMAMMADOV
AHMET MURAT ÇAKMAK

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
BAHADIR, GÜLNUR GÖLLÜ; ERGÜN, ERGUN; TELLİ, ONUR; KHANMAMMADOV, FARİD; and ÇAKMAK,
AHMET MURAT (2016) "Hormone therapy in hypospadias surgery: a survey on the current practice in
Turkey," Turkish Journal of Medical Sciences: Vol. 46: No. 6, Article 2. https://doi.org/10.3906/
sag-1507-72
Available at: https://journals.tubitak.gov.tr/medical/vol46/iss6/2

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2016) 46: 1624-1628
© TÜBİTAK
doi:10.3906/sag-1507-72

http://journals.tubitak.gov.tr/medical/

Research Article

Hormone therapy in hypospadias surgery: a survey on the current practice in Turkey
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Background/aim: Nowadays surgical intervention is possible in smaller phalluses and younger children with hypospadias disease.
Different hormone treatments with different doses, modalities, indications, and treatment times come along with some disputes. The
aim of this study is to evaluate the management approaches in hypospadias surgery of surgeons in regards to hormone preparations.
Materials and methods: Questionnaires were sent via e-mail to 110 actively working pediatric surgeons and urologists. The answers of
99 surgeons were evaluated (90%). Two surgeons declared that they did not perform hypospadias surgery.
Results: When testosterone usage in penile surgery was questioned, 44.4% of participants (n = 44) answered positively. Small-short
penis glans, narrow urethral plate, chordee, disorders of sexual development, buccal mucosa-graft operations, slight tissue, and
defective ventral skin were the indications for usage. Forty of forty-four surgeons stated usage in proximal hypospadias, 18 of them in
penile hypospadias, and 15 of them in distal hypospadias. The most common form was dihydrotestosterone (62%). According to the
respondents, fistulas (83%), infections (78%), and wound dehiscence (77%) were reduced. Fifty-six percent of the surgeons stated that
bleeding was increased and 39% stated easier dissection.
Conclusion: As a result of this questionnaire we can understand that there is no standard usage of testosterone in Turkey. Optimal
points of usage can be introduced by increasing prospective randomized trials and education programs can ensure similar effective
usage.
Key words: Dihydrotestosterone, hormone, hypospadias, testosterone

1. Introduction
Hypospadias is a congenital penile abnormality that
is defined as an abnormal proximal location of the
urethral meatus on the ventral penis and often includes
ventral foreskin deficiency and ventral penile curvature
(1,2). Hormone therapy preceding surgical correction is
indicated to obtain better surgical conditions. However,
there is divergence in the literature regarding the hormone
therapy of choice, time of its use before surgery, appropriate
dose, and route of application.
In recent years androgen stimulation with testosterone
(T) and dihydrotestosterone (DHT) have been proven
to have significant effects on favoring better local skin
conditions; promoting phallic growth, making surgical
correction easier; and resulting in fewer complications
and temporarily increasing penile length and glans
circumference (3–5), whereas there is controversy with
conflicting studies demonstrating negative effects of
androgens in hypospadias surgery (6–8). Furthermore,
there is considerable variability in clinical practice of the
* Correspondence: cakmakma@hotmail.com
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hormone therapy of choice, topical or parenteral usage,
time of use, and dose of therapy. We surveyed pediatric
surgeons and urologists to determine the current practices
for androgen therapy of hypospadias surgery in Turkey.
2. Materials and methods
A multiple-choice questionnaire was emailed to
practitioners, inviting them to participate in a survey
regarding the use of preoperative androgens, indications
for treatment, dosing, administration schedule, and
complications. No reminders were sent and a 2-week
period was given prior to the closing of the study and
beginning of data analysis. Ethical approval was not
required for this study.
3. Results
Ninety-nine of 110 (90%) surgeons who received the
e-mail invitation completed the survey; 70 were pediatric
surgeons and 29 were urologists. The majority of responses
came within the first week. Length of time in practice
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with hypospadias surgery varied from 5 to 20 years for
the majority of 97 of 99 respondents. Two surgeons
declared that they did not perform hypospadias surgery.
Of all respondents, 44 (44.4%) used T in daily practice
(hypospadias, infertility, etc.). Of the 53 prescribers not
using T, 4 cited ineffectiveness, difficulties in obtaining
drugs, and high rates of complication previously and
abandoned T therapy; 4 stated that such therapy was given
by a pediatric endocrinologist and the others reported no
previous experience or no need for hormone therapy.
Small or short appearing penis, reduced glans
circumference, reduced urethral plate width, chordee,
ambiguous genitalia, and grafting of buccal mucosa were
the main indications for hormone therapy in hypospadias
surgery.
Forty (90.9%) of 44 responders preferred using T in
proximal hypospadias, whereas 15 of them used it in distal
hypospadias surgery. Of the respondents, 31.9% (31/97)
used DHT in practice. Nineteen percent of providers used
parenteral T whereas sixty-four of them preferred topical
and seventeen used both of them. The administration
schedule for testosterone was less than 3 weeks in 11
responders, 4 to 6 weeks in 14, and more than 6 weeks in
17 prior to surgery.
Penile appearance, penile length, glans circumference,
increased urethral plate width, and reduced rigidity
of buccal mucosa grafts were the effects of T that were
mentioned by the responders in the multiple-choice
questionnaire. Additionally, practitioners reported that
enough growth of the penis, increased glans circumference,
increased penile length, end of the predetermined
regimen, reduced rigidity in buccal mucosa, and adverse
effects (priapism, hirsutism, etc.) were the indications that
physicians should stop giving androgens. Demographic
data of respondents and T usage parameters are listed in
Table 1.
The number of physicians reporting T use by the age of
<3 years was 22, at 3 to 5 years was 24, at 6 to 10 years was
14, and at 11 to 17 years was 5. Urethrocutaneous fistula,
infection, and wound dehiscence were the long-term
complications reported by physicians. Peroperative and
postoperative complications were bleeding, edema, ease
of dissection, use of tourniquet, use of cauterization, and
wound healing. Details of complications are listed in Table
2. Almost all of the physicians in hypospadias surgery did
not replace the suture type or suturing technique after T
therapy; however, 2 responders replaced the operation
technique after hormone therapy.
4. Discussion
Our survey highlights the diversity in types of hormone
therapy and especially T, application time, type of
application, giving up therapy, age range for therapy,

peroperative results, and surgical parameters. Our study
demonstrates that hormone therapy in hypospadias
surgery reveals a variation among pediatric surgeons
and urologists; however, surgeons’ experience and habits
revealed a weighted spread.
A 97% response rate was obtained from 99 surgeons
who had hypospadias surgery in practice, and 44.4% of
them reported hormone therapy in hypospadias surgery.
In a recent survey by Springer et al., 10.9% of the 377
participants used preoperative androgen regularly (4). In
another study, Malik et al. reported a higher T use (78%)
among pediatric urologists (9).
Similar to previous reports (10–12), in our study,
we have found that T use was common in 40 (90.9%) of
44 applicants when proximal hypospadias was present.
However, Ratan et al. reported that not only one anatomical
factor, such as meatal location or the severity of chordee,
should be considered alone with respect to the hormonal
profile of isolated hypospadias. Multiple anatomical
factors may improve hormonal supplementation for longterm surgical outcomes (13).
Preoperative androgen stimulation has been reported
to increase glans circumference and penile length, and/
or improve preputial vascularization before hypospadias
surgery.
On the other hand, there are not enough data in the
literature about dosing recommendations with various
regimens of intramuscular or topical androgens before
repair. As there is no established protocol for such
evaluations, Snodgrass et al. reported that 63% of patients
received preoperative T stimulation based on glans width
of <14 mm, which is less than the average normal newborn
glans diameter, without previous endocrine testing (14).
Multiple studies with different types of T therapy
and with different doses and times of application were
reported. Those studies showed an advantage with a
statistically significant increase in penile length and glans
circumference, as well as induction of neovascularization
(3,12,15,16).
In a recent international survey associated with
pediatric surgery, pediatric urology, urology, and plastic
surgery, it was documented that 108 participants (39.4%)
used topical DHT, 120 (43.8%) used intramuscular T,
43 (15.7%) used T cream, and 3 (1.1%) used β-human
chorionic gonadotropin (β-hCG) in practice. In the
literature different hormones were reported by different
authors, such as testosterone enanthate, propionate,
DHT cream, and β-hCG (3,9,14,16). In our study, DHT
(56.8%), testosterone enanthate (7.8%), β-hCG (15.6%),
and testosterone cypionate (5.8%) were the main types of
hormones used by physicians.
Two reports compared the use of parenteral and
topical T and examined significant penile growth with

1625

GÖLLÜ BAHADIR et al. / Turk J Med Sci
Table 1. Demographic data of respondents and testosterone use.

Length of time in practice with hypospadias surgery
<5 years
6–10 years
11–15 years
>16 years

n (%)
26 (26.2%)
27 (26.2%)
17 (26.2%)
27 (26.2%)

Testosterone use in daily practice
Yes
No

n (%)
44 (44.4%)
53 (53.5%)

Indications for testosterone use (multiple answers)
Small or short appearing penis
Reduced glans circumference
Reduced urethral plate width
Chordee
Ambiguous genitalia
Prior or after grafting of buccal mucosa
Other (thin epidermis)

36
21
5
2
18
8
3

Forms of testosterone (multiple answers)
Testosterone cypionate
Testosterone enanthate
Dihydrotestosterone
β-hCG
Others

3 (5.8%)
4 (7.8%)
29 (56.8%)
8 (15.6%)
7 (13.7%)

Time for testosterone use prior to surgery
<3 weeks
4 to 6 weeks
6 weeks

11
14
17

Determination of testosterone effect
Penile appearance
Penile length
Glans circumference
Increased urethral plate width
Reduced rigidity in buccal mucosa graft

30
13
28
11
6

Indications to stop giving testosterone
Enough growth of penis
Increased glans circumference
Increased penile length
End of the predetermined regimen
Reduced rigidity in buccal mucosa
Adverse effects (priapism, hirsutism, etc.)

19
13
7
21
4
11

no difference between the two types of administration
(17,18). Some studies compared both parenteral and
topical T use and found that topical use of T has more side
effects of pigmentation of the genitals, appearance of pubic
hair, and skin irritation at the site of application (16–18).
Similarly, Monfort et al. found that adverse effects were
also observed when DHT was used topically, suggesting
that intramuscular hormone therapy is preferable to
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topical therapy (19). Contrarily, in our study we found that
the physicians mainly chose topical administration as it is
easy to apply and to avoid the systemic effects of parenteral
use.
There is no general agreement about the time of
application and giving up therapy. In a recent review,
intramuscular treatment was reported to be proposed to
last 3 months, consisting of a monthly application of T,
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Table 2. Complications after testosterone therapy.
Complications (long-term)
Urethrocutaneous fistula
Increased
Decreased
No difference
Infection
Increased
Decreased
No difference
Wound dehiscence
Increased
Decreased
No difference
Peroperative and postoperative complications
Bleeding
Increased
Decreased
No difference
Edema
Increased
Decreased
No difference
Ease of dissection
Increased
Decreased
No difference
Use of tourniquet
Increased
Decreased
No difference
Use of cauterization
Increased
Decreased
No difference
Wound healing
Increased
Decreased
No difference

2
15
1
1
7
1
2
10
1

23
0
18
11
0
29
16
5
20
4
0
36
11
0
28
6
4
31

while topical treatment should last on average 3 to 4 weeks,
with 2 daily applications (3). In our survey, 50% of the
participants answered that the average time of application
was 3–4 weeks. On the other hand, the cessation of therapies

prior to surgery was reported by 36% within 2 weeks and
by 31% within 3 to 4 weeks. Similarly, in a previous report,
topical T use was ceased in all patients 1 week prior to
surgery, whereas in another study doses of intramuscular T
were skipped if penile length and glans circumference had
noticeably increased with the first does or first two doses
(12,15). Mostly studies failed to report a time of cessation.
In another report, monthly intramuscular injections were
stopped when penile length was at or above 35 mm (20).
In a recent study by Malik et al., the timing of cessation of
preoperative T was reported as a risk factor for surgical
complications and the predetermined regimen was the
major factor for the cessation of therapy (9).
There are not enough data in the literature evaluating
the intra- and postoperative effects of hormone therapy.
There are some studies reporting that absence of
intraoperative complications mainly referred to an absence
of important bleeding during surgical time (12,17). Our
results show that 56% of physicians experience an increase
in bleeding, whereas 44% of them reported no difference.
Mostly edema, ease of dissection, use of tourniquet, use
of cauterization, and wound healing were reported with
no differences. According to responders, long-term
complications of urethrocutaneous fistula, infection,
and wound dehiscence were reported to decrease in our
study. On the other hand, two studies with long-term
surgical outcomes reported fewer fistulas and a change in
the type of surgery required, avoiding the use of pedicle
flaps and tube repairs in 25% of the boys, with a significant
reduction in glanular dehiscence and meatal stenosis and
a decreased need for reoperation (16,21). However, in our
study, none of the physicians reported a change in surgical
technique related to the surgical technique for hypospadias
repair chosen after the child is under anesthesia and can be
evaluated better.
In this survey, we highlighted current national trends
in current practice of T therapy. There is no consensus
on standardization of T therapy in Turkey, like all
over the world. Future prospective studies focusing on
standardized dosing and administration of T regimens are
needed to compare results. Although many hypospadias
surgery techniques are identified and reported to be
effective, hormone therapy will be beneficial in some cases
of hypospadias surgery as a supportive treatment.
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